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A population often contains distinct sub-populations, thereby increasing the complexity of
the overall heterogeneity. However, the cellular origin and biological relevance of sub-popu-
lations in cell population have not been clearly identified. Here we demonstrated the novel
roles of ISGylation, which is an IFN-induced post-translational modification, controlling het-
erogeneity at the population level in cultured adherent cells. Without UBE1L, an E1 enzyme
of ISGylation, mouse embryonic fibroblasts (MEF) exhibited low viral resistance despite
high STAT1 and ISG expression compared with the wild-type MEF. We observe that
Ube1l−/−MEF populations consist of two behaviorally distinguishable sub-populations with
distinct basal STAT1 activity, while wild-type MEF populations are unimodal. This popula-
tion heterogeneity in Ube1l knock-out cells was perturbed by tyrosine kinase inhibitors,
AG490 and PF431396. In contrast, the neutralization of type I IFN did not affect population
heterogeneity. Based on these results, we concluded that UBE1L functions to adjust basal
immunological states with the regulation of population heterogeneity.
Introduction
In biological systems, most populations consist of heterogeneous sub-populations with differ-
ent characteristics but not identical individuals. Classically, the heterogeneities at the genetic
level such as nucleotide polymorphism, genome mutation, and chromosome instability are
considered as sources of various biological phenomena, including evolution, speciation, pheno-
typic divergence and disease development [1–3]. At the non-genetic level, the heterogeneity in
epigenetic regulations of the genome such as DNA methylation, histone modification, and
chromatin structures have been also suggested as sources of various biological processes [3, 4].
In addition, intrinsic stochastic behavior of macromolecules previously considered as noise has
been recently considered as a non-genetic source of heterogeneity within populations, which
contributes to the diversity of cellular responses to changing environmental conditions [5, 6].
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The co-existence of multiple states, independent to genetic heterogeneity, has been reported in
various biological systems [7–9]. The resistant sub-populations confer survival against antibi-
otics or chemotherapy in bacteria or cancer cells [10, 11] and latency in human immunodefi-
ciency virus integration [12]. During viral infection, multiple host factors, including the history
of infection, cellular state of development, stages of cell cycle progression, and even the cellular
morphology, are known to affect the cellular heterogeneity of host response against the virus
[13]. Type I Interferon(IFN), which is the most potent anti-viral agent produced by the host,
functions to disable the infected host cells, to induce the cell-intrinsic anti-viral state, and to
activate the host immunity against infection [14]. The anti-viral effect of type I IFN is primarily
mediated by IFN-stimulated genes (ISG), which are induced by the Janus kinase (JAK)-signal
transducer and activator of transcription (STAT) pathway [15]. During anti-viral responses,
the production of type I IFN is highly stochastic, since only a small fraction of virus-infected
cells produce IFNs, while the infected neighboring cells go through the bystander effect [16,
17]. Different levels of signaling factors and receptors in the basal state prior to viral infection
and the IFNβ-mediated feedback loop have been proposed as the source of the cellular hetero-
geneity that results in the stochastic IFN production, conferring viral clearance with the host
survival [17, 18]. Although the consequences of cellular heterogeneity during viral infection are
relatively well known, the control of population heterogeneity and the regulation of anti-viral
responses are not understood.
ISGylation is a post-translational modification process that requires a cascade of enzymatic
activities to conjugate IFN-stimulated gene 15 (ISG15) to target proteins [19]. The expression
of ISG15, the enzymes responsible for its conjugation, and cellular target proteins such as
DDX58, IRF3, PKR, and STAT1 are strongly induced by treatment of type I IFNs or viral infec-
tion [19]. These results indicate that ISGylation plays critical roles in the regulation of anti-
viral immunity. However, ISGylation-deficient mice exhibit complicated phenotypes against
virus infection: their susceptibility to infection by vesicular stomatitis virus and lymphocytic
choriomeningitis virus is unchanged [20], while their susceptibility to infection by influenza B
virus infection is increased [21, 22], compared with wild-type mice. Furthermore, the cellular
targets of ISGylation are not exclusive to proteins in anti-viral responses, but include constitu-
tive proteins with known cellular functions in cytoskeletal organization, stress responses, tran-
scription, and even translation [23, 24]. These characteristics suggest that the function of
ISGylation is neither restricted to the regulation of a single target protein nor explained by the
regulation of immune signaling strength.
In this study, we demonstrated the potential role of ISGylation in the blockage of population
heterogeneity to enhance anti-viral immunity. We found that two separable sub-populations
with distinct basal productions of type I IFN and ISGs appear in basal Ube1l deficient cells.
With these results, the regulation of population heterogeneity and the potential roles of ISGyla-
tion on anti-viral responses were discussed.
Materials and Methods
Cell, virus and reagent
Mouse embryonic fibroblasts(MEF) from wild type and Ube1l-/- mice [20] (provided by Dr. K.I
Kim, Sookmyung Women’s University, Korea) were maintained in Dulbecco’s modified eagle
medium (DMEM) (Welgene, Korea) supplemented with 10% Fetal bovine serum (FBS)
(Hyclone, Logan, UT) and 1% penicillin/streptomycin (Invitrogen, Carlsbad, CA). Influenza A
virus (PR8 strain) was obtained from Dr. Adolfo Garcia-Sastre, Mount Sinai School of Medi-
cine, USA and Sendai virus (VR-907™) was acquired from ATCC (Manasas, VA). For infection,
cells were incubated with viruses in serum free DMEM for 1 hour and washed with PBS
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followed by further incubation with DMEM (10% FBS) until indicated time (including initial
incubation time). Recombinant mouse IFNβ was purchased from PBL (Piscataway, NJ). Puri-
fied anti-mouse Interferon alpha/beta receptor 1 (IFNAR-1) (#127301) and mouse IgG1, κ as
isotype control (#400101) used for neutralization was purchased from Biolegend (San Diego,
CA). The cytokine and antibody are treated to the cells with desired concentration in DMEM
(10% FBS) for indicated times. AG490 was purchase from Invivogen (San Diego, CA).
SB20219, SP600125, U0126 and PD98059 were purchased from Sigma (St. Louis, MO). Jak
inhibitor 1 was purchased from Merck (Kenilworth, NJ). Chemical drugs were dissolved to
Dimethyl sulfoxide (DMSO) (Sigma, St. Louis, MO). DMSO was used for the control. Puromy-
cin used for the mammalian cell selection was purchased from A.G Scientific. Inc (San Diego,
CA).
Lentiviral transduction
pMSCV-puro-HA-UBE1L was generated for lentiviral transduction of human UBE1L. The
human UBE1L tagged with HA in amino-terminus from pCAGGs-HA-UBE1L[25] was poly-
merase chain reaction (PCR) amplified with a pair of oligonucleotides (5-gcgaattcgccaccatg-
tacccatacgac-3, 5-gcgaattctcacagctcatagtgcagag-3), followed by digestion with EcoRI. The PCR
products were ligated into pMSCV-puro digested with EcoRI. pLL3.7-shIfnar1 was purchased
(Bioneer, Korea) for lentiviral transduction of short-hairpin RNA targeting mouse specific
Ifnar1 (gcgtctacattatagatgac aa). Lentiviruses were generated and prepared as previously
described [26]. Purified lentiviruses were used to treat Ube1l+/+ and Ube1l-/- MEFs in serum-
free DMEM for 12 h. After washing with phosphate buffered saline, the cells were cultured in
DMEM (10% FBS, 1% penicillin/streptomycin) for 48 h. The selection process using puromy-
cin (10 μg/ml) was performed in human UBE1L-transduced MEFs, followed by single colony
selection and amplification. To measure the knockdown effect of Ifnar1, GFP-positive cells
were selectively analyzed among the shIfnar1-transduced MEFs.
FACS analysis
To measure the surface expression of H-2Kb, cells were washed with fluorescence associated
cell sorter (FACS) buffer (1% FBS in phosphate buffered saline), followed by staining with anti-
H-2Kb conjugated with FITC or PE (#553569 or #553570, BD Pharmingen, San Diego, CA).
To measure the total internal expression of H-2Kb, cells were fixed with 4% paraformaldehyde
and permeabilized with 0.1% saponin (Sigma) in FACS buffer. Fixed and permeabilized cells
were stained with anti-H-2Kb conjugated with FITC or PE. Stained cells were washed with
FACS buffer and analyzed with a flow cytometer (FACSCalibur™, BD Biosciences, San Jose,
CA). To sort cells according to H-2Kb expression levels, a flow cytometer associated with a cell
sorting system (FACSAria™, BD Bioscience; Moflo™ XDP, Beckman Coulter, Brea, CA) was
used.
Total RNA preparation, real time quantitative and semi-quantitative PCR
Total RNAs were prepared using RNAiso plus (TAKARA, Japan). 500ng of RNA were reverse
transcribed with oligo-dT (for cellular genes) or random hexamer (for viral genes) using
ImProm-II Reverse transcriptase system (Promega, Madison, WI). Quantitative realtime PCR
of cDNA were performed with StepOne Plus Real-Time PCR system (Applied Biosystems, Fos-
ter City, CA). Using the same cDNA acquired from reverse transcripation reaction, routine
semi-quantitative PCR was performed and analyzed by agarose gel electrophoresis with EtBr
staining. Sequence information of oligonucleotide used for this study is provided in S1 Table.
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Immunoblot analysis
Cells were lysed with lysis buffer (150 mMNaCl, 25 mM Tris–HCl, pH 7.4, 1% Triton X-100,
0.5% Deoxycholic acid, 0.1% SDS) supplemented with protease inhibitors and phosphatase
inhibitors. Total lysates (10-30ug) were separated on SDS-PAGE and transferred to nitrocellu-
lose membranes. The expressions of interested proteins were analyzed using specific antibodies
according to manufacturer’s protocol. Antibodies used for immunoblot analysis were listed in
S2 Table.
Results
Ube1l−/−MEFs basally express high levels of anti-viral genes but exhibit
low viral resistance
UBE1L is an E1 enzyme that is required for the conjugation of ISG15 to target proteins [20].
To understand the effects of ISGylation in the anti-viral response, we first measured the expres-
sion of various genes required for anti-viral responses in Ube1l−/−mouse embryonic fibroblasts
(MEFs). As previously reported [20], Ube1l−/−MEF did not show any significant defect in anti-
viral protein expressions such as DDX58, LGP2, and PKR upon IFNβ treatment (Fig 1A). Con-
sistent with that, IFNβ-mediated activation of STAT1 (phosphorylation at Tyr 701 residue)
which is required for ISG expressions was also not significantly altered in Ube1l−/−MEFs (Fig
1B). These results indicate that UBE1L does not play any significant regulatory roles in type I
IFN signaling pathways. However, the effects of ISGylation deficiency were mainly exerted in
Fig 1. TheUbe1l-deficient MEFs are more susceptible to viruses with higher STAT1 activity. (A) Immunoblot assay for
measuring expression of indicated genes inUbe1l+/+ andUbe1l-/-MEF with or without IFNβ (100 U/ml, 16 hour). (B)
Immunoblot assay for measuring STAT1 activity (phosphorylation of Tyr701 on STAT1) in in Ube1l+/+ andUbe1l-/-MEFs with
or without IFNβ (100 U/ml, 30 min). (C) Relative mRNA expression of the indicated genes in basal Ube1l+/+ andUbe1l-/-
MEFs. Left–Using real-time quantitative PCR, normalizing withGapdh. Right–Representative agarose gel image using
conventional reverse-transcription PCR. Numbers beside image indicate the size of PCR product (base pairs). (D)
Intracellular viral RNA normalizing withGapdh inUbe1l+/+ andUbe1l-/-MEFs infected with influenza A virus (10 TCID50) for
the indicated time. (E) Relative amounts of intracellular viral RNA normalizing withGapdh inUbe1l+/+ andUbe1l-/-MEFs
infected with Sendai virus (10 TCID50) for indicated time. (A-B) Numbers beside blot images indicate the molecular weight
(kDa). (C-E) Mean and standard error obtained from three independent experiments, unpaired t test, * p<0.05, ** p<0.01,
***p<0.001.
doi:10.1371/journal.pone.0159453.g001
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the basal state. ISG expression and the STAT1 phosphorylation of the basal Ube1l−/−MEF
were significantly higher than that of the wild-type cells. In the basal condition, mRNA expres-
sion of various ISGs, including Oas1a, Isg15, and Stat1, was significantly increased in ISGyla-
tion-deficient Ube1l−/−MEFs (Fig 1C); the same was observed for Ifnb1. Despite higher levels
of basal STAT1 activity and anti-viral ISG expression, Ube1l−/− cells were more susceptible to
viral infection (Fig 1D and 1E). These results suggest that the functions of UBE1L protein
cannot simply explained by the overall expression levels of anti-viral genes in the cellular
population.
Ube1l deficient cells generate two sub-populations of distinct STAT1
activity
Because the total STAT1 activity was not correlated with the cellular responses against viral
infection, we examined the heterogeneity of basal STAT1 activity within the whole population.
Therefore, we monitored the cell-cell variations of STAT1 activity by measuring the surface
presentation of class I MHC (H-2Kb). Its surface presentation is known to be induced by acti-
vated STAT1 [27]. In the population of Ube1l+/+ cells, the surface H-2Kb expression was
homogeneous, with unimodal distributions (Fig 2A and 2B). Upon stimulation with IFNβ, the
whole population of the Ube1l+/+ MEFs shifted to the right, indicating that surface H-2Kb
expression was uniformly enhanced in this cell type. While the surface H-2Kb expression
observed in Ube1l+/+ cells was unimodal, in Ube1l−/− cells, it was bimodal and heterogeneous
Fig 2. Ube1l-deficient population harbors sub-populations with distinct surface H-2Kb expression. (A) FACS analysis of surface H-2Kb
expression onUbe1l+/+MEFs with indicated amount of IFNβ for 16hour. (B) FACS analysis of surface H-2Kb expression on Ube1l+/+ and MEFs, with
100U/ml of IFNβ for indicated time. (C) FACS analysis of surface H-2Kb expression onUbe1l-/-MEFs with indicated amount of IFNβ for 16hour. (D) FACS
analysis of surface H-2Kb expression onUbe1l-/- and MEFs, with 100U/ml of IFNβ for indicated time. (E) With or without the treatment of IFNβ (100U/ml,
16 h), Ube1l+/+ andUbe1l-/-MEFs were harvested and permeabilized followed by FACS analysis for the whole cell H-2Kb expression. (F) Top—FACS
analysis of surface H-2Kb expression onUbe1l+/+ andUbe1l-/-MEFs transduced with the control or HA-hUBE1L-lentivirus. Bottom—Immunoblot for
confirming HA-UBE1L expression. Numbers beside blot images indicate the molecular weight (kDa).
doi:10.1371/journal.pone.0159453.g002
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with one sub-population showing low surface H-2Kb and another showing high H-2Kb expres-
sion (Fig 2C and 2D). Upon stimulation with IFNβ, the H-2Kblow sub-population shifted to the
right and merged to the H-2Kbhigh sub-population. Meanwhile, the total intracellular H-2Kb
protein levels were unimodal in both Ube1l+/+ and Ube1l−/− cells (Fig 2E), indicating that the
bimodal surface presentation of H-2Kb does not happen due to changes in the steps of H-2Kb
production. To examine whether the segregation of sub-population observed in the Ube1l−/−
cells was caused by the lack of UBE1L, a lentiviral vector containing HA-hUBE1L was trans-
duced into the Ube1l-/- cells (Fig 2F). This reconstitution abrogated the bimodality of Ube1l−/−
cells, resulting in homogeneous surface H-2Kb expression, confirming that UBE1L is responsi-
ble for population segregation.
To determine whether the Ube1l−/− sub-populations with distinct surface H-2Kb expression
exhibit distinct STAT1 activity, each sub-population was separately sorted according to H-2Kb
expression (H-2Kbhigh and H-2Kblow) with FACS, and expression of various ISGs was mea-
sured (Fig 3A and 3B). Consistent with the results for surface H-2Kb, the H-2Kbhigh cells
expressed higher levels of ISGs compared to the H-2Kblow cells. Using the mean intensity value
to separate the sub-populations of Ube1l−/− cells, we also artificially sorted Ube1l+/+ cells and
measured ISGs (Fig 3C). Unlike Ube1l−/− cells, significant differences in ISG expression were
not observed in wild-type cells. Consistent with ISG and Ifnb1 expression, STAT1 phosphory-
lation levels in the sorted Ube1l−/−MEF were revealed to be different with higher STAT1 phos-
phorylation on H-2Kbhigh than on H-2Kblow, while no significant difference was observed in
sorted Ube1l+/+ MEF (Fig 3D). Based on these findings, we conclude that the UBE1L functions
Fig 3. Two sub-populations ofUbe1l-/-MEFs possesses distinct basal STAT1 activity. (A) TheUbe1l-/- sub-
populations with high and low H-2Kb expression (H and L, respectively) were sorted using FACS and subjected to
immunoblot assays with indicated antibodies. (B) Relative mRNA expression of the indicated genes in theUbe1l-/-
sorted according to H-2Kb expression. (C) Ube1l+/+MEF were sorted using the intensity value that separates H-
2Kbhigh and H-2Kblow Ube1l-/-, and relative mRNA expression of the indicated genes were measured. (D) Immunoblot
assay for measuring basal STAT1 activity ofUbe1l+/+ and Ube1l-/-MEFs sorted separately according to surface H-
2Kb expression. (A, D) Numbers beside blot images indicate the molecular weight (kDa). (B, C) Left–Using real-time
quantitative PCR, normalizing withGapdh. Mean and standard error obtained from three independent experiments,
unpaired t test, * p<0.05, ** p<0.01, ***p<0.001. Right–Representative agarose gel image using conventional
reverse-transcription PCR. Numbers beside image indicate the size of PCR product (base pairs).
doi:10.1371/journal.pone.0159453.g003
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to control population segregation based on its differential basal STAT1 activity and ISG
expressions.
Bimodal STAT1 activity is not mediated by basal type I IFN signaling
In search for signals that regulate basal STAT1 activity in Ube1l−/− cells, we first examined the
effect of basal Type I IFN. Type I IFN is a major agonist for STAT1 activation and ISG expres-
sion during the viral infection [14, 15]. Furthermore, significantly different amounts of basal
Ifnb1mRNA expressions were detected between two sub-population of Ube1l−/−MEF (Fig
3C). To test this possibility, the neutralizing antibody of type I IFN receptor (IFNAR1) was
treated to block the basal type I IFN signaling activity and the population heterogeneity was
measured (Fig 4A). Despite the neutralization, two sub-populations were still present in
Ube1l−/−MEFs. The inhibition of type I IFN signaling activities with the lentiviral transduction
of shRNA specific for mouse Ifnar1 also did not alter the bimodality of Ube1l−/−MEFs (Fig
4B). Consistent with these results, the inhibition of JAK activities with the chemical inhibitor
(Jak Inhibitor I) did not alter the bimodality in Ube1l−/−MEFs, although with complete inhibi-
tion of type I IFN signaling (Fig 4C and 4D). These results imply that the bimodality of basal
STAT1 activity in Ube1l−/−MEFs are not mediated by type I IFN or type I IFN-mediated sig-
naling pathways.
Kinase inhibitors, AG490 and PF431396, abrogate bimodality of basal
STAT1 in Ube1l−/−MEFs
To elucidate the intracellular signaling responsible for the maintenance of bimodality of
Ube1l−/−MEF, we examined other kinases that are known to affect STAT1 activity. Therefore,
Fig 4. Bimodality inUbe1l deficient MEF populations are not mediated by basal type I IFN signaling. (A) FACS analysis of
surface H-2Kb expression on MEFs treated with a neutralizing antibody for IFNAR1 (5 μg/ml) or the isotype control. (B) Left—FACS
analysis of surface H-2Kb expression in MEFs transduced with the control or mouse Ifnar1 shRNA lentivirus. Right–Relative
expression of Ifnar1mRNA normalizing withGapdh in control or Ifnar1 shRNA lentivirus treated MEF. (C-D) Ube1l+/+ (C) andUbe1l-/-
(D) were treated with 10uM of Jak Inhibitor 1 (Jak Inh 1) for 4 hours followed by additional 12 hours of IFNβ (100U/ml) treatment.
Samples were harvested and measure the H-2Kb expression with FACS.
doi:10.1371/journal.pone.0159453.g004
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we first tested the effect of mitogen-activated protein kinases, using SP600125 (inhibitor of
JNK), SP202190 (inhibitor of p38), PD98059 (inhibitor of MEK1/2), or U0126 (inhibitor of
MEK1/2). However, none of these chemical inhibitors exhibited a significant change in the
bimodality of basal surface H-2Kb expression in Ube1l−/−MEF (Fig 5A). In contrast, AG490,
tyrosine kinase inhibitor known to inhibit epidermal growth factor receptor (EGFR), in addi-
tion to JAK2, abrogated the bimodality of basal H-2Kb expression (Fig 5B). While the Ube1l+/+
cells were not significantly affected, AG490 treatment led the H-2Kbhigh group to merge with
the H-2Kblow group in Ube1l−/− cells. Similarly, PF431396, a kinase inhibitor known to inhibit
FAK1 and PYK2, affected the population heterogeneity (Fig 5C). Upon PF431396 treatment,
the H-2Kbhigh sub-population shifted to the H-2Kblow group in Ube1l−/−MEFs.
To address whether AG490-sensitive kinase activity controls the basal STAT1 activity
observed in Ube1l−/−MEFs, we measured the basal phosphorylation of STAT1 (Tyr701) in
Ube1l−/−-/- MEFs with the AG490 treatment (Fig 6A). Active STAT1 was strongly reduced in
the AG490-treated Ube1l−/− cells, resulting similar levels of STAT1 phosphorylation observed
in Ube1l+/+. Consistent with that, the protein expressions of various anti-viral ISGs, including
STAT1 itself, were significantly reduced in the same experimental samples. AG490 also signifi-
cantly reduced mRNA expression of various ISGs in Ube1l−/− cells (Fig 6B). However, expres-
sion of Ifnb1mRNA was not significantly altered by AG490 treatment, suggesting that STAT1
bimodality is not responsible for the type I IFN synthesis.
Fig 5. AG490 and PF431396 block the bimodality in basal surface H-2Kb expression ofUbe1l deficient MEFs. (A) Ube1l+/+ andUbe1l-/-
MEF were treated with indicated chemical inhibitor (16hour, indicated amount), and were analyzed by FACS for surface H-2Kb expression.
SP600125 is JNK inhibitor, SB202190 is p38 inhibitor, and both PD98059 and U0126 are MEK1/2 inhibitors. (B) Surface H2Kb expression in
MEFs treated with AG490 (16 h, indicated amount). (C) Surface H2Kb expression in MEFs treated with PF431396 (16 h, indicated amount).
doi:10.1371/journal.pone.0159453.g005
Regulation of Population Heterogeneity of Basal STAT1 Activity
PLOS ONE | DOI:10.1371/journal.pone.0159453 July 18, 2016 8 / 13
Similar to AG490, PF431396-sensitive kinase also affected the basal STAT1 activity in
Ube1l−/−MEFs (Fig 6C). We measured the basal activity of STAT1 after PF431396 treatment.
As the phosphorylation of FAK1 (Tyr397) and PYK2 (Tyr402) were reduced by PF431396
treatment, phosphorylated form of STAT1 was also reduced. Furthermore, FAK inhibition also
lowered the expression levels of ISGs, but not of Ifnb1 (Fig 6D). From these results, we con-
clude that the cellular tyrosine kinases affected by AG490 and PF431396 inhibitors are respon-
sible for the bimodality of basal STAT1 activity and ISG expression in Ube1l-deficient cells.
Discussion
Our data suggest that UBE1L functions to prevent population heterogeneity, which originates
from the bimodal STAT1 activity. Using the ISGylation-deficient Ube1l−/− cells, we found that
UBE1L suppresses basal STAT1 activity in the overall population of the cells, but also increases
Fig 6. Effect of AG490 and PF431396 inhibitor on basal STAT1 activity and ISG expression. (A)
Immunoblot assay for measuring basal STAT1 activity and expression of indicated genes in MEFs treated
with AG490 (50 μM, 16 h). (B) Relative mRNA expression of the indicated genes were measured in MEFs
treated with AG490 (50 μM, 16hr). (C) Immunoblot assay for measuring basal STAT1 activity and expression
of indicated genes in MEFs treated with PF431396 (10 μM, indicated time). Numbers above the blot denotes
treatment time in hours. (D) Relative mRNA expression of the indicated genes were measured in MEFs
treated with PF431396 (15 μM, 12 h). (A, C) Numbers beside blot images indicate the molecular weight
(kDa). (B, D) Top–Using real-time quantitative PCR, normalizing withGapdh. Mean and standard error
obtained from three independent experiments, unpaired t test, * p<0.05, ** p<0.01, ***p<0.001. Bottom–
Representative agarose gel image using conventional reverse-transcription PCR. Numbers beside image
indicate the size of PCR product (base pairs).
doi:10.1371/journal.pone.0159453.g006
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the resistance against the viral infection. During research to solve this contradiction, it was
revealed that Ube1l−/−MEFs populations consisted of two sub-populations with distinct basal
STAT1 activities. This population segregation was revealed to be originated from the basal
kinase activity sensitive to AG490 and PF431396, but not from the constitutive type I IFN
activity present in the basal states.
In the present study, the basal signals that resulted in the bimodality of STAT1 in Ube1l−/−
MEF are still elusive. Considering the result of the use of a neutralizing antibody and shRNA
against type I IFN receptor, we excluded the involvement of type I IFN in this process. We also
excluded the involvement of type II and type III IFNs in population segregation of the Ube1l−/−
MEFs, because Jak Inhibitor 1 that is known to inhibit JAK1, JAK2, and TYK1, which are
involved in IFN signaling, did not show any significant effect [28–30]. Instead, we propose that
the tyrosine kinases sensitive to AG490 or PF431396 is responsible for the bimodality of
STAT1 in Ube1l−/−MEFs. While AG490 targets various kinases, including JAK2, EGFR, and
ERBB2 [31, 32], PF431396 targets for both FAK1 and PYK2 [33], which are members of the
FAK family. Based on the results acquired with the pan-JAK inhibitor (Jak Inhibitor 1), by
excluding JAK2, we suspected that EGFR, ERBB2, FAK1 or Pyk2 were candidate kinases
responsible for the basal STAT1 activity. The association of EGFR and FAK signaling pathway
has been previously reported [34, 35]. During the growth factor-induced cell migration or
adhesion, EGFR is known to associate with the integrin receptors and form multi-protein sig-
naling complexes [36]. Both FAK and STAT1 are reported to be found in this complex [35, 37–
39]. Therefore, it is logical to consider basal growth factor or cell adhesion signaling activities
as potential sources of bimodality observed in Ube1l-deficient cells.
The basal population heterogeneity that we observed in Ube1l-deficient MEFs appeared in
the conventional culture method. However, in physiological circumstances, various environ-
mental stresses are persistently applied to the cellular population [40, 41]. These environmental
factors, working as selection pressures, determine population dynamics with multiple levels of
non-genetic and genetic heterogeneity [3, 42–44]. Although we applied the type I IFN or chem-
ical inhibitors and observed the change of population composition of MEFs, the effects of pro-
longed stresses were not considered in this research. Considering the selection effect of long-
term persisting stresses on the biological systems, including cancer development [3, 42], further
researches monitoring population dynamics upon prolonged stresses are required for identify-
ing the cause and the physiological meaning of cellular heterogeneity. In those experiments,
the dynamics of population originated from genetic heterogeneity should be also considered.
In this study, we presented the effect of population heterogeneity in the regulation of anti-
viral signaling. Beneficial or detrimental outcomes of population heterogeneity may depend on
the nature of the changing environment or selection pressures [45]. In a harsh environment
with restricted resources, increasing heterogeneity with multiple sub-populations may confer
benefits of cooperation with the reduction of intra-population competition for the overall fit-
ness of the entire population [46, 47]. Meanwhile, reducing heterogeneity restricts individuals
to extreme behaviors, which are wasteful in a moderate environment [45]. The disruption of
population heterogeneity regulation frequently results in disease progression, particularly can-
cer [3, 11, 48]. During the stepwise development of the majority of cancer, genetic heterogene-
ity is highly increased by chromosome instability with non-clonal chromosome aberration
required for the progression to the next stage [42]. In addition to that, phenotypic diversifica-
tion originated from non-genetic heterogeneity is also observed in a cancer cell population,
resulting in the occurrence of drug resistant sub-populations [11]. These results imply that the
regulation of population heterogeneity is essential to maintain the homeostasis of biological
systems. However, in host-virus interaction, the physiological meaning of population heteroge-
neity has not been extensively studied. Although the working mechanism of how the
Regulation of Population Heterogeneity of Basal STAT1 Activity
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heterogeneity affects host anti-viral immunity remained to be answered, our study suggests the
potential roles of ISGylation on the host anti-viral response with the regulation of population
heterogeneity.
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